| Â | Perioda,b | OSNRC | SNC |
|---|
Clinical adverse event | 1 | 0 | 0 |
2 | 0 | 0 |
Severe adverse event | 1 | 0 | 0 |
2 | 0 | 0 |
pCO2 > 45 mmHg | 1 | 0 | 0 |
2 | 0 | 0 |
pH < 7.35 | 1 | 2 (25)c | 1 (12) |
2 | 1 (17) | 2 (25) |
Lactate > 3 mmol/L | 1 | 0 | 2 (25) |
2 | 1 (17)d | 0 |
SpO2 < 90% despite O2 | 1 | 0 | 0 |
2 | 0 | 0 |
- Data represent the number (percent) of patients who experienced an adverse event with OSNRC and SNC (control)
- aDuring Period 1, patients were treated with OSNRC (Group A, n = 8) or SNC (Group B, n = 8) for 1 hour
- bDuring Period 2, patients were treated with OSNRC (Group B, n = 6) or SNC (Group A, n = 8) for 1 hour
- cP > 0.99 for difference between OSNRC and SNC treatments
- dP = 0.43 for difference between OSNRC and SNC treatments
